Drug Device Combination Products Market by Type (Injectable, Transdermal Patch, Infusion Pump, Drug-eluting Stent, Inhaler), Application (Diabetes, Oncology, Pain, Opthamology), End User (Hospital, Home Care), and Region - Global Forecast to 2030

1 INTRODUCTION 29 1.1 STUDY OBJECTIVES 29 1.2 MARKET DEFINITION 29 1.3 STUDY SCOPE 30 1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE 30 1.3.2 INCLUSIONS & EXCLUSIONS 31 1.3.3 YEARS CONSIDERED 31 1.3.4 CURRENCY CONSIDERED 32 1.4 STAKEHOLDERS 32 2 RESEARCH METHODOLOGY 33 2.1 RESEARCH DATA 33 2.1.1 SECONDARY DATA 34 2.1.1.1 Key sources of secondary data 34 2.1.1.2 Key data from secondary sources 35 2.1.2 PRIMARY DATA 35 2.1.2.1 Key objectives of primary research 36 2.1.2.2 Key industry insights 37 2.1.2.3 Breakdown of primaries 37 2.2 MARKET SIZE ESTIMATION 38 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH) 39 2.2.2 MNM REPOSITORY ANALYSIS 41 2.2.3 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS 41 2.2.4 TOP-DOWN APPROACH 41 2.3 MARKET GROWTH RATE PROJECTION 42 2.4 DATA TRIANGULATION 43 2.5 STUDY ASSUMPTIONS 44 2.6 RESEARCH LIMITATIONS 44 2.7 RISK ANALYSIS 45 3 EXECUTIVE SUMMARY 46 4 PREMIUM INSIGHTS 51 4.1 DRUG DEVICE COMBINATION PRODUCTS MARKET OVERVIEW 51 4.2 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION AND COUNTRY 52 4.3 DRUG DEVICE COMBINATION PRODUCTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53   5 MARKET OVERVIEW 54 5.1 INTRODUCTION 54 5.2 MARKET DYNAMICS 54 5.2.1 DRIVERS 55 5.2.1.1 Rising prevalence of chronic diseases 55 5.2.1.2 Growing adoption of biologics and vaccines 57 5.2.1.3 High R&D investments from government organizations and private bodies 58 5.2.1.4 Shift toward personalized medicines and patient-centric care 59 5.2.1.5 Rising popularity of self-administered medicines 59 5.2.2 RESTRAINTS 59 5.2.2.1 Stringent regulatory policies and compliance hurdles 59 5.2.2.2 Focus on alternative drug delivery methods 60 5.2.3 OPPORTUNITIES 60 5.2.3.1 Increased preference for minimally invasive products 60 5.2.3.2 High growth potential in emerging economies 61 5.2.3.3 Growing adoption of drug device combination products and expanding biologics market 61 5.2.4 CHALLENGES 62 5.2.4.1 Heavy financial impact of drug wastage and device malfunction 62 5.2.4.2 Lack of standardized reimbursement policies 62 5.2.4.3 Limited training and education for healthcare professionals 63 5.2.4.4 Lack of medical specialists and surgeons 63 5.3 INDUSTRY TRENDS 63 5.3.1 RISING POPULARITY OF SELF-ADMINISTERED MEDICINES AND HOME CARE SETTINGS 63 5.3.2 INTEGRATION OF DRUG DEVICE COMBINATION PRODUCTS WITH SMART CONNECTED DEVICES 64 5.4 TECHNOLOGY ANALYSIS 64 5.4.1 KEY TECHNOLOGIES 64 5.4.1.1 Wearable technologies 64 5.4.1.2 Drug-eluting technologies 65 5.4.2 COMPLEMENTARY TECHNOLOGIES 65 5.4.2.1 Connected health and digital technologies 65 5.4.3 ADJACENT TECHNOLOGIES 66 5.4.3.1 Advanced materials and biopolymers 66 5.5 PORTER’S FIVE FORCES ANALYSIS 67 5.5.1 THREAT OF NEW ENTRANTS 68 5.5.2 THREAT OF SUBSTITUTES 68 5.5.3 BARGAINING POWER OF SUPPLIERS 68 5.5.4 BARGAINING POWER OF BUYERS 69 5.5.5 INTENSITY OF COMPETITIVE RIVALRY 69   5.6 KEY STAKEHOLDERS & BUYING CRITERIA 69 5.6.1 KEY STAKEHOLDERS IN BUYING PROCESS 69 5.6.2 KEY BUYING CRITERIA 70 5.7 REGULATORY ANALYSIS 71 5.7.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71 5.7.2 REGULATORY FRAMEWORK 74 5.7.2.1 North America 74 5.7.2.1.1 US 74 5.7.2.1.2 Canada 76 5.7.2.2 Europe 77 5.7.2.3 Asia Pacific 78 5.7.2.3.1 India 78 5.7.2.3.2 China 78 5.7.2.3.3 Japan 78 5.7.2.4 Latin America 79 5.7.2.5 Middle East & Africa 79 5.8 PATENT ANALYSIS 80 5.8.1 KEY PATENTS GRANTED 81 5.9 TRADE ANALYSIS 82 5.9.1 TRADE ANALYSIS FOR PREFILLED SYRINGES (HS CODE 300431), 2019–2023 82 5.9.1.1 Import data for HS Code 300431 82 5.9.1.2 Export data for HS Code 300431 83 5.9.2 TRADE DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), 2019–2023 83 5.9.2.1 Import data for HS Code 300431 84 5.9.2.2 Export data for HS Code 300431 85 5.10 PRICING ANALYSIS 85 5.10.1 INDICATIVE PRICING OF DRUG DEVICE COMBINATION PRODUCTS, BY KEY PLAYER, 2024 86 5.10.2 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DELIVERY DEVICES, BY KEY PLAYER, 2022–2024 87 5.10.3 AVERAGE SELLING PRICE TREND OF DRUG DELIVERY COMBINATION PRODUCTS, BY REGION, 2022–2024 87 5.10.3.1 Average selling price trend for pen injectors, 2022–2024 88 5.10.3.2 Average selling price trend for inhalers, 2022–2024 88 5.10.3.3 Average selling price trend for drug-eluting stents, 2022–2024 88 5.11 VALUE CHAIN ANALYSIS 89 5.12 KEY CONFERENCES & EVENTS, 2025–2026 90 5.13 UNMET NEEDS/END-USER EXPECTATIONS 91 5.14 ADJACENT MARKET ANALYSIS 92 5.15 ECOSYSTEM ANALYSIS 92 5.15.1 ROLE IN ECOSYSTEM 93 5.16 CASE STUDY ANALYSIS 94 5.16.1 MINIMED 780G DIABETES MANAGEMENT SYSTEM TO COMBINE CONTINUOUS GLUCOSE MONITORING WITH AUTOMATED INSULIN DELIVERY 94 5.16.2 DIGIINHALER-SMART INHALER FOR ASTHMA/COPD TO TRACK LUNG FUNCTION 94 5.16.3 ADOPTION OF PEN INJECTORS BY NEMERA FRANCE TO IMPROVE THERAPEUTIC OUTCOMES 95 5.17 SUPPLY CHAIN ANALYSIS 95 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 97 5.19 INVESTMENT & FUNDING SCENARIO 98 5.20 REIMBURSEMENT SCENARIO ANALYSIS 98 5.21 CLINICAL PIPELINE ANALYSIS 99 5.22 IMPACT OF AI/GEN AI ON DRUG DEVICE COMBINATION PRODUCTS MARKET 102 5.23 IMPACT OF 2025 US TARIFF ON DRUG DEVICE COMBINATION PRODUCTS MARKET 103 5.23.1 KEY TARIFF RATES 104 5.23.2 PRICE IMPACT ANALYSIS 105 5.23.3 IMPACT ON COUNTRY/REGION 106 5.23.3.1 North America 106 5.23.3.1.1 US 106 5.23.3.2 Europe 106 5.23.3.3 Asia Pacific 106 5.23.4 IMPACT ON END-USE INDUSTRIES 107 5.23.4.1 Hospitals & clinics 107 5.23.4.2 Ambulatory surgery centers 107 5.23.4.3 Long-term care facilities 107 5.23.4.4 Home care settings 107 6 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE 108 6.1 INTRODUCTION 109 6.2 INJECTABLE DRUG DELIVERY DEVICES 109 6.2.1 PREFILLED SYRINGES 112 6.2.1.1 Need to eliminate dosing mistakes and improve patient compliance to drive segment 112 6.2.2 PEN INJECTORS 113 6.2.2.1 Ease of self-administration and improved dosage accuracy to fuel adoption 113 6.2.3 AUTOINJECTORS 116 6.2.3.1 Ease of use and better patient experience to aid adoption in emergency medical conditions 116 6.2.4 WEARABLE INJECTORS 118 6.2.4.1 Rising popularity of embedded wireless devices to propel market growth 118 6.2.5 NEEDLE-FREE INJECTORS 120 6.2.5.1 Reduced risk of needlestick injury to fuel market adoption 120 6.3 DRUG-ELUTING STENTS 122 6.3.1 LOW RATE OF RESTENOSIS TO PROPEL MARKET GROWTH 122 6.4 INHALERS 124 6.4.1 INCREASING PREVALENCE OF RESPIRATORY DISEASES TO FUEL UPTAKE 124 6.5 INFUSION PUMPS 126 6.5.1 RISING NUMBER OF SURGICAL PROCEDURES TO FUEL DEMAND FOR AMBULATORY INFUSION PUMPS 126 6.6 TRANSDERMAL PATCHES 128 6.6.1 RISING INCIDENCE OF CHRONIC DISEASES REQUIRING LONG-TERM MEDICATION TO AID MARKET GROWTH 128 6.7 DRUG-COATED BALLOONS 130 6.7.1 ABILITY TO DELIVER LOCALIZED DRUG THERAPY WITH MINIMAL SYSTEMIC EXPOSURE TO DRIVE MARKET 130 6.8 OTHER PRODUCT TYPES 131 7 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION 133 7.1 INTRODUCTION 134 7.2 DIABETES MANAGEMENT 134 7.2.1 HIGH GERIATRIC POPULATION AND INCREASED SEDENTARY LIFESTYLE TO PROPEL MARKET GROWTH 134 7.3 RESPIRATORY DISEASES 137 7.3.1 RISE IN URBANIZATION, AIR POLLUTION, AND SMOKING TO FUEL RESPIRATORY AILMENTS 137 7.4 OPTHALMOLOGY 139 7.4.1 RISE OF DIABETIC EYE DISEASES AND FAVORABLE REGULATORY SCENARIO TO AUGMENT MARKET GROWTH 139 7.5 AUTOIMMUNE DISEASES 140 7.5.1 NEED FOR PROLONGED TREATMENT IN CHRONIC PATIENTS TO SPUR MARKET GROWTH 140 7.6 ONCOLOGY 142 7.6.1 DRUG DEVICE COMBINATION PRODUCTS TO AID THERAPEUTIC PRECISION AND OPTIMIZE PATIENT OUTCOMES DURING CANCER TREATMENT 142 7.7 INFECTIOUS DISEASES 144 7.7.1 IRREGULARIZED URBANIZATION AND POOR SANITATION IN EMERGING ECONOMIES TO PROPEL MARKET GROWTH 144 7.8 CARDIOVASCULAR DISEASES 145 7.8.1 INCREASE IN SEDENTARY LIFESTYLE AND CHANGES IN EATING HABITS TO FUEL MARKET GROWTH 145 7.9 OBESITY MANAGEMENT 147 7.9.1 INCREASING PREVALENCE OF OBESITY TO SUPPORT MARKET GROWTH 147 7.10 PAIN MANAGEMENT 149 7.10.1 BETTER PATIENT ADHERENCE AND MINIMAL SIDE EFFECTS TO DRIVE ADOPTION OF TRANSDERMAL PATCHES 149 7.11 OTHER APPLICATIONS 150 8 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER 152 8.1 INTRODUCTION 153 8.2 HOSPITALS & CLINICS 153 8.2.1 ACCESS TO MULTI-DISCIPLINARY EXPERTISE AND PROCEDURE-BASED CARE TO AID MARKET GROWTH 153 8.3 AMBULATORY SURGERY CENTERS 155 8.3.1 NEED FOR COST-EFFECTIVE AND HIGH-QUALITY MINIMALLY INVASIVE TREATMENT TO SUPPORT MARKET GROWTH 155 8.4 LONG-TERM CARE FACILITIES 157 8.4.1 INCREASING INCIDENCE OF CHRONIC DISEASES AMONG ELDERLY AND DISABLED POPULATION TO DRIVE MARKET 157 8.5 HOME CARE SETTINGS 159 8.5.1 INCREASING DEMAND FOR PATIENT-CENTRIC AND COST-EFFECTIVE HEALTHCARE TO PROPEL MARKET GROWTH 159 8.6 OTHER END USERS 161 9 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION 163 9.1 INTRODUCTION 164 9.2 NORTH AMERICA 165 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 165 9.2.2 US 169 9.2.2.1 US to dominate North American drug device combination products market during forecast period 169 9.2.3 CANADA 172 9.2.3.1 Regulatory modernization and strategic government investments to augment market growth 172 9.3 EUROPE 175 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 175 9.3.2 GERMANY 178 9.3.2.1 Technological advancements and strong R&D infrastructure to propel market growth 178 9.3.3 UK 181 9.3.3.1 Strong emphasis on personalized and value-based healthcare to aid market growth 181 9.3.4 FRANCE 184 9.3.4.1 Strong healthcare infrastructure and high investments in biopharmaceutical innovation to boost market growth 184 9.3.5 ITALY 187 9.3.5.1 Focus on pharmaceutical-meditech convergence and healthcare modernization to drive market 187 9.3.6 SPAIN 190 9.3.6.1 Increasing geriatric population and growing focus on home-based treatment to propel market growth 190 9.3.7 REST OF EUROPE 193   9.4 ASIA PACIFIC 195 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 195 9.4.2 CHINA 199 9.4.2.1 Favorable government policies and increased healthcare spending to support market growth 199 9.4.3 JAPAN 202 9.4.3.1 Advanced healthcare systems and universal reimbursement policies to spur market growth 202 9.4.4 INDIA 205 9.4.4.1 Growing focus on digital health integration and booming biosimilars sector to drive market 205 9.4.5 SOUTH KOREA 208 9.4.5.1 Robust R&D infrastructure and enhanced focus on government-industry collaborations to aid market growth 208 9.4.6 AUSTRALIA 211 9.4.6.1 Rising healthcare investments by government and private organizations to boost market growth 211 9.4.7 REST OF ASIA PACIFIC 214 9.5 LATIN AMERICA 216 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 216 9.5.2 BRAZIL 219 9.5.2.1 Presence of universal healthcare system and high geriatric population to drive market 219 9.5.3 MEXICO 221 9.5.3.1 Focus on nearshoring and improvement in healthcare sector to drive market 221 9.5.4 REST OF LATIN AMERICA 224 9.6 MIDDLE EAST & AFRICA 226 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 226 9.6.2 GCC COUNTRIES 229 9.6.2.1 Kingdom of Saudi Arabia 232 9.6.2.1.1 Developed medical tourism and favorable government initiatives to support market growth 232 9.6.2.2 UAE 235 9.6.2.2.1 Increased prevalence of diabetes and focus on innovative patient-centric care to drive market 235 9.6.2.3 Rest of GCC countries 237 9.6.3 REST OF MIDDLE EAST & AFRICA 239 10 COMPETITIVE LANDSCAPE 242 10.1 INTRODUCTION 242 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 242 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET 242   10.3 REVENUE ANALYSIS, 2020–2024 244 10.4 MARKET SHARE ANALYSIS, 2024 245 10.4.1 RANKING OF KEY MARKET PLAYERS 250 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 251 10.5.1 STARS 251 10.5.2 EMERGING LEADERS 251 10.5.3 PERVASIVE PLAYERS 251 10.5.4 PARTICIPANTS 251 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 253 10.5.5.1 Company footprint 253 10.5.5.2 Region footprint 254 10.5.5.3 Product type footprint 255 10.5.5.4 Application footprint 256 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 257 10.6.1 PROGRESSIVE COMPANIES 257 10.6.2 RESPONSIVE COMPANIES 257 10.6.3 DYNAMIC COMPANIES 257 10.6.4 STARTING BLOCKS 257 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 259 10.6.5.1 Detailed list of key startups/SME players 259 10.6.5.2 Competitive benchmarking of key startups/SME players 259 10.7 COMPANY VALUATION & FINANCIAL METRICS 260 10.7.1 FINANCIAL METRICS 260 10.7.2 COMPANY VALUATION 260 10.8 BRAND/PRODUCT COMPARISON 261 10.9 COMPETITIVE SCENARIO 261 10.9.1 PRODUCT LAUNCHES AND APPROVALS 261 10.9.2 DEALS 262 10.9.3 EXPANSIONS 263 10.9.4 OTHER DEVELOPMENTS 265 11 COMPANY PROFILES 266 11.1 KEY PLAYERS 266 11.1.1 ABBOTT 266 11.1.1.1 Business overview 266 11.1.1.2 Products offered 267 11.1.1.3 Recent developments 268 11.1.1.3.1 Product launches and approvals 268 11.1.1.3.2 Deals 269 11.1.1.4 MnM view 269 11.1.1.4.1 Right to win 269 11.1.1.4.2 Strategic choices 269 11.1.1.4.3 Weaknesses & competitive threats 269 11.1.2 ELI LILLY AND COMPANY 270 11.1.2.1 Business overview 270 11.1.2.2 Products offered 271 11.1.2.3 Recent developments 273 11.1.2.3.1 Product approvals 273 11.1.2.3.2 Deals 274 11.1.2.3.3 Expansions 275 11.1.2.3.4 Other developments 276 11.1.2.4 MnM view 276 11.1.2.4.1 Right to win 276 11.1.2.4.2 Strategic choices 276 11.1.2.4.3 Weaknesses & competitive threats 277 11.1.3 MEDTRONIC 278 11.1.3.1 Business overview 278 11.1.3.2 Products offered 279 11.1.3.3 Recent developments 281 11.1.3.3.1 Product launches and approvals 281 11.1.3.3.2 Deals 282 11.1.3.4 MnM view 282 11.1.3.4.1 Right to win 282 11.1.3.4.2 Strategic choices 282 11.1.3.4.3 Weaknesses & competitive threats 283 11.1.4 NOVO NORDISK A/S 284 11.1.4.1 Business overview 284 11.1.4.2 Products offered 285 11.1.4.3 Recent developments 286 11.1.4.3.1 Product launches and approvals 286 11.1.4.3.2 Deals 287 11.1.4.3.3 Expansions 288 11.1.4.4 MnM view 289 11.1.4.4.1 Right to win 289 11.1.4.4.2 Strategic choices 289 11.1.4.4.3 Weaknesses & competitive threats 290 11.1.5 NOVARTIS AG 291 11.1.5.1 Business overview 291 11.1.5.2 Products offered 292 11.1.5.3 Recent developments 294 11.1.5.3.1 Product approvals 294 11.1.5.3.2 Deals 294 11.1.5.3.3 Expansions 295   11.1.5.4 MnM view 295 11.1.5.4.1 Right to win 295 11.1.5.4.2 Strategic choices 295 11.1.5.4.3 Weaknesses & competitive threats 296 11.1.6 SANOFI 297 11.1.6.1 Business overview 297 11.1.6.2 Products offered 298 11.1.6.3 Recent developments 299 11.1.6.3.1 Product approvals 299 11.1.6.3.2 Deals 300 11.1.6.3.3 Other developments 301 11.1.7 BOSTON SCIENTIFIC CORPORATION 302 11.1.7.1 Business overview 302 11.1.7.2 Products offered 303 11.1.7.3 Recent developments 305 11.1.7.3.1 Product approvals 305 11.1.7.3.2 Deals 305 11.1.8 BECTON, DICKINSON AND COMPANY 306 11.1.8.1 Business overview 306 11.1.8.2 Products offered 307 11.1.8.3 Recent developments 308 11.1.8.3.1 Deals 308 11.1.8.3.2 Other developments 308 11.1.9 MERCK KGAA 309 11.1.9.1 Business overview 309 11.1.9.2 Products offered 310 11.1.9.3 Recent developments 311 11.1.9.3.1 Deals 311 11.1.10 ABBVIE INC. 312 11.1.10.1 Business overview 312 11.1.10.2 Products offered 313 11.1.10.3 Recent developments 314 11.1.10.3.1 Product approvals 314 11.1.10.3.2 Deals 315 11.1.10.3.3 Expansions 315 11.1.11 TEVA PHARMACEUTICAL INDUSTRIES LTD. 316 11.1.11.1 Business overview 316 11.1.11.2 Products offered 317 11.1.11.3 Recent developments 318 11.1.11.3.1 Product approvals 318 11.1.11.3.2 Other developments 318   11.1.12 STRYKER 319 11.1.12.1 Business overview 319 11.1.12.2 Products offered 320 11.1.13 B. BRAUN SE 321 11.1.13.1 Business overview 321 11.1.13.2 Products offered 322 11.1.14 TERUMO CORPORATION 323 11.1.14.1 Business overview 323 11.1.14.2 Products offered 324 11.1.14.3 Recent developments 325 11.1.14.3.1 Product launches and approvals 325 11.2 OTHER PLAYERS 326 11.2.1 TANDEM DIABETES CARE, INC. 326 11.2.2 CEQUR SIMPLICITY 326 11.2.3 INTARCIA THERAPEUTICS, INC. 327 11.2.4 HALOZYME, INC. 327 11.2.5 KALEO, INC. 328 11.2.6 LEAD CHEMICAL CO., LTD. 329 11.2.7 PURDUE PHARMA L.P. 329 11.2.8 ALVOGEN 330 11.2.9 EVOLUTIS 330 11.2.10 MUNDIPHARMA INTERNATIONAL LIMITED 331 11.2.11 SPARSHA PHARMA INTERNATIONAL PVT. LTD. 332 11.2.12 SUPERNUS PHARMACEUTICALS, INC. 333 11.2.13 ALCON INC. 334 12 APPENDIX 335 12.1 DISCUSSION GUIDE 335 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 342 12.3 CUSTOMIZATION OPTIONS 344 12.4 RELATED REPORTS 344 12.5 AUTHOR DETAILS 345

TABLE 1 DRUG DEVICE COMBINATION PRODUCTS MARKET: INCLUSIONS & EXCLUSIONS 31 TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 32 TABLE 3 DRUG DEVICE COMBINATION PRODUCTS MARKET: STUDY ASSUMPTIONS 44 TABLE 4 DRUG DEVICE COMBINATION PRODUCTS MARKET: RISK ANALYSIS 45 TABLE 5 DIABETES POPULATION WORLDWIDE, 2024 VS. 2050 (MILLION) 55 TABLE 6 DRUG DEVICE COMBINATION PRODUCTS MARKET: PORTER’S FIVE FORCES 68 TABLE 7 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF DRUG DEVICE COMBINATION PRODUCTS 70 TABLE 8 KEY BUYING CRITERIA FOR DRUG DEVICE COMBINATION PRODUCTS 70 TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 71 TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 72 TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73 TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 74 TABLE 14 US: CLASSIFICATION AND APPROVAL PATHWAYS 75 TABLE 15 US: CLASSIFICATION OF MEDICAL EQUIPMENT 75 TABLE 16 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 75 TABLE 17 CANADA: CLASSIFICATION OF DRUG DEVICE COMBINATION PRODUCTS 76 TABLE 18 CANADA: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 77 TABLE 19 EUROPE: EUROPEAN REGULATORY FRAMEWORK FOR DRUG DEVICE COMBINATION PRODUCTS 77 TABLE 20 EUROPE: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 77 TABLE 21 CHINA: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 78 TABLE 22 JAPAN: RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS 79 TABLE 23 DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY PATENTS GRANTED, JANUARY 2022−APRIL 2025 81 TABLE 24 IMPORT DATA FOR PREFILLED SYRINGES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND) 82 TABLE 25 EXPORT DATA FOR PREFILLED SYRINGES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND) 83 TABLE 26 IMPORTS DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND) 84 TABLE 27 EXPORT DATA FOR TRANSDERMAL PATCHES (HS CODE 300431), BY COUNTRY, 2019–2023 (USD THOUSAND) 85 TABLE 28 INDICATIVE PRICING OF DRUG DEVICE COMBINATION PRODUCTS, BY KEY PLAYER, 2024 86 TABLE 29 AVERAGE SELLING PRICE TREND OF INJECTABLE DRUG DEVICE DELIVERY DEVICES, BY KEY PLAYER, 2022–2024 87 TABLE 30 AVERAGE SELLING PRICE TREND FOR PEN INJECTORS, BY REGION, 2022–2024 88 TABLE 31 AVERAGE SELLING PRICE TREND FOR INHALERS, BY REGION, 2022–2024 88 TABLE 32 AVERAGE SELLING PRICE TREND FOR DRUG-ELUTING STENTS, BY REGION, 2022–2024 88 TABLE 33 DRUG DEVICE COMBINATION PRODUCTS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 90 TABLE 34 DRUG DEVICE COMBINATION PRODUCTS MARKET: ROLE IN ECOSYSTEM 93 TABLE 35 CASE STUDY 1: MINIMED 780G DIABETES MANAGEMENT SYSTEM TO COMBINE CONTINUOUS GLUCOSE MONITORING WITH AUTOMATED INSULIN DELIVERY 94 TABLE 36 CASE STUDY 2: DIGIINHALER-SMART INHALER FOR ASTHMA/COPD TO TRACK LUNG FUNCTION 94 TABLE 37 CASE STUDY 3: ADOPTION OF PEN INJECTORS BY NEMERA FRANCE TO IMPROVE THERAPEUTIC OUTCOMES 95 TABLE 38 DRUG DEVICE COMBINATION PRODUCTS MARKET: REIMBURSEMENT SCENARIO ANALYSIS 98 TABLE 39 DRUG DEVICE COMBINATION PRODUCTS MARKET: CLINICAL PIPELINE ANALYSIS (AS OF MARCH 2025) 99 TABLE 40 US-ADJUSTED RECIPROCAL TARIFF RATES 104 TABLE 41 KEY PRODUCT-RELATED TARIFF FOR DRUG DEVICE PRODUCTS 105 TABLE 42 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 109 TABLE 43 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 110 TABLE 44 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY COUNTRY, 2023–2030 (USD BILLION) 111 TABLE 45 LIST OF KEY PREFILLED SYRINGES AVAILABLE IN MARKET 112 TABLE 46 PREFILLED SYRINGES MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 113 TABLE 47 LAUNCH OF KEY GLP-1-RELATED INJECTABLES BY MAJOR PHARMACEUTICAL COMPANIES, 2010–2024 114 TABLE 48 LIST OF KEY PEN INJECTORS AVAILABLE IN MARKET 114 TABLE 49 PEN INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 115 TABLE 50 LIST OF KEY AUTOINJECTORS AVAILABLE IN MARKET 116 TABLE 51 AUTOINJECTORS MARKET, BY COUNTRY 2023–2030 (USD BILLION) 117 TABLE 52 TOP FIVE COUNTRIES WITH HIGHEST NUMBER OF DIABETES PATIENTS (20–79 YEARS), 2021 VS. 2045 (MILLION) 118 TABLE 53 LIST OF KEY WEREABLE INJECTORS AVAILABLE IN MARKET 119 TABLE 54 WEARABLE INJECTORS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 119 TABLE 55 LIST OF KEY NEEDLE-FREE INJECTORS AVAILABLE IN MARKET 120 TABLE 56 NEEDLE-FREE INJECTORS MARKET, BY COUNTRY 2023–2030 (USD BILLION) 121 TABLE 57 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DRUG-ELUTING STENTS, BY COUNTRY, 2023–2030 (USD BILLION) 123 TABLE 58 LIST OF KEY INHALERS AVAILABLE IN MARKET 124 TABLE 59 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INHALERS, BY COUNTRY, 2023–2030 (USD BILLION) 125 TABLE 60 LIST OF KEY INFUSION PUMPS AVAILABLE IN MARKET 126 TABLE 61 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INFUSION PUMPS, BY COUNTRY, 2023–2030 (USD BILLION) 127 TABLE 62 LIST OF KEY TRANSDERMAL PATCHES AVAILABLE IN MARKET 128 TABLE 63 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR TRANSDERMAL PATCHES, BY COUNTRY, 2023–2030 (USD BILLION) 129 TABLE 64 LIST OF KEY DRUG-COATED BALLOONS AVAILABLE IN MARKET 130 TABLE 65 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DRUG-COATED BALLOONS, BY COUNTRY, 2023–2030 (USD BILLION) 131 TABLE 66 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER PRODUCT TYPES, BY COUNTRY, 2023–2030 (USD BILLION) 132 TABLE 67 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 134 TABLE 68 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR DIABETES MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION) 136 TABLE 69 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 138 TABLE 70 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2023–2030 (USD BILLION) 140 TABLE 71 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AUTOIMMUNE DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 141 TABLE 72 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR ONCOLOGY, BY COUNTRY, 2023–2030 (USD BILLION) 143 TABLE 73 KEY DRUG DEVICE COMBINATION PRODUCTS AVAILABLE FOR INFECTIOUS DISEASES 144 TABLE 74 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 145 TABLE 75 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2023–2030 (USD BILLION) 146 TABLE 76 KEY DRUG DEVICE COMBINATION PRODUCTS AVAILABLE FOR OBESITY MANAGEMENT 147 TABLE 77 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OBESITY MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION) 148 TABLE 78 KEY TRANSDERMAL PATCHES AVAILABLE FOR PAIN MANAGEMENT 149 TABLE 79 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR PAIN MANAGEMENT, BY COUNTRY, 2023–2030 (USD BILLION) 150 TABLE 80 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2023–2030 (USD BILLION) 151 TABLE 81 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 153 TABLE 82 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2023–2030 (USD BILLION) 154 TABLE 83 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AMBULATORY SURGERY CENTERS, BY COUNTRY, 2023–2030 (USD BILLION) 156 TABLE 84 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD BILLION) 158 TABLE 85 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2023–2030 (USD BILLION) 160 TABLE 86 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023–2030 (USD BILLION) 162 TABLE 87 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION, 2023–2030 (USD BILLION) 164 TABLE 88 TRANSDERMAL PATCHES MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 164 TABLE 89 DRUG-ELUTING STENTS MARKET, BY REGION, 2023–2030 (THOUSAND UNITS) 165 TABLE 90 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 166 TABLE 91 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 167 TABLE 92 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 167 TABLE 93 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 168 TABLE 94 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 168 TABLE 95 US: KEY MACROINDICATORS 169 TABLE 96 US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 170 TABLE 97 US: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 170 TABLE 98 US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 171 TABLE 99 US: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 171 TABLE 100 CANADA: KEY MACROINDICATORS 172 TABLE 101 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 173 TABLE 102 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 173 TABLE 103 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 174 TABLE 104 CANADA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 174 TABLE 105 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 175 TABLE 106 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 176 TABLE 107 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 176 TABLE 108 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 177 TABLE 109 EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 177 TABLE 110 GERMANY: KEY MACROINDICATORS 178 TABLE 111 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 179 TABLE 112 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 179 TABLE 113 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 180 TABLE 114 GERMANY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 180 TABLE 115 UK: KEY MACROINDICATORS 181 TABLE 116 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 182 TABLE 117 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 182 TABLE 118 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 183 TABLE 119 UK: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 183 TABLE 120 FRANCE: KEY MACROINDICATORS 184 TABLE 121 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 185 TABLE 122 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 185 TABLE 123 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 186 TABLE 124 FRANCE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 186 TABLE 125 ITALY: KEY MACROINDICATORS 187 TABLE 126 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 188 TABLE 127 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 188 TABLE 128 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 189 TABLE 129 ITALY: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 189 TABLE 130 SPAIN: KEY MACROINDICATORS 190 TABLE 131 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 191 TABLE 132 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 191 TABLE 133 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 192 TABLE 134 SPAIN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 192 TABLE 135 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 193 TABLE 136 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 194 TABLE 137 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, APPLICATION, 2023–2030 (USD BILLION) 194 TABLE 138 REST OF EUROPE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 195 TABLE 139 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 197 TABLE 140 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 197 TABLE 141 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 198 TABLE 142 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 198 TABLE 143 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 199 TABLE 144 CHINA: KEY MACROINDICATORS 200 TABLE 145 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 200 TABLE 146 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 201 TABLE 147 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 201 TABLE 148 CHINA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 202 TABLE 149 JAPAN: KEY MACROINDICATORS 202 TABLE 150 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 203 TABLE 151 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 203 TABLE 152 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 204 TABLE 153 JAPAN: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 204 TABLE 154 INDIA: KEY MACROINDICATORS 205 TABLE 155 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 206 TABLE 156 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 206 TABLE 157 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, APPLICATION, 2023–2030 (USD BILLION) 207 TABLE 158 INDIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 207 TABLE 159 SOUTH KOREA: KEY MACROINDICATORS 208 TABLE 160 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 209 TABLE 161 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 209 TABLE 162 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 210 TABLE 163 SOUTH KOREA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 210 TABLE 164 AUSTRALIA: KEY MACROINDICATORS 211 TABLE 165 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 212 TABLE 166 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 212 TABLE 167 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 213 TABLE 168 AUSTRALIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 213 TABLE 169 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 214 TABLE 170 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 214 TABLE 171 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 215 TABLE 172 REST OF ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 215 TABLE 173 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 216 TABLE 174 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 217 TABLE 175 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 217 TABLE 176 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 218 TABLE 177 LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 218 TABLE 178 BRAZIL: KEY MACROINDICATORS 219 TABLE 179 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 219 TABLE 180 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 220 TABLE 181 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 220 TABLE 182 BRAZIL: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 221 TABLE 183 MEXICO: KEY MACROINDICATORS 221 TABLE 184 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 222 TABLE 185 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 222 TABLE 186 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 223 TABLE 187 MEXICO: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 223 TABLE 188 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 224 TABLE 189 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 225 TABLE 190 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 225 TABLE 191 REST OF LATIN AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 226 TABLE 192 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY REGION, 2023–2030 (USD BILLION) 227 TABLE 193 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 227 TABLE 194 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 228 TABLE 195 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 228 TABLE 196 MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 229 TABLE 197 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY COUNTRY, 2023–2030 (USD BILLION) 230 TABLE 198 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 230 TABLE 199 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 231 TABLE 200 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 231 TABLE 201 GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 232 TABLE 202 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 233 TABLE 203 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 233 TABLE 204 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 234 TABLE 205 KINGDOM OF SAUDI ARABIA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 234 TABLE 206 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 235 TABLE 207 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 236 TABLE 208 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 236 TABLE 209 UAE: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 237 TABLE 210 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 237 TABLE 211 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 238 TABLE 212 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 238 TABLE 213 REST OF GCC COUNTRIES: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 239 TABLE 214 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2023–2030 (USD BILLION) 239 TABLE 215 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2023–2030 (USD BILLION) 240 TABLE 216 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2023–2030 (USD BILLION) 240 TABLE 217 REST OF MIDDLE EAST & AFRICA: DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2023–2030 (USD BILLION) 241 TABLE 218 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET 242 TABLE 219 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR AUTOINJECTORS: DEGREE OF COMPETITION 246 TABLE 220 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR PEN INJECTORS: DEGREE OF COMPETITION 247 TABLE 221 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR TRANSDERMAL PATCHES: DEGREE OF COMPETITION 248 TABLE 222 DRUG DEVICE COMBINATION PRODUCTS MARKET: REGION FOOTPRINT 254 TABLE 223 DRUG DEVICE COMBINATION PRODUCTS MARKET: PRODUCT TYPE FOOTPRINT 255 TABLE 224 DRUG DEVICE COMBINATION PRODUCTS MARKET: APPLICATION FOOTPRINT 256 TABLE 225 DRUG DEVICE COMBINATION PRODUCTS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 259 TABLE 226 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS 259 TABLE 227 DRUG DEVICE COMBINATION PRODUCTS MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 261 TABLE 228 DRUG DEVICE COMBINATION PRODUCTS MARKET: DEALS, JANUARY 2022–MARCH 2025 262 TABLE 229 DRUG DEVICE COMBINATION PRODUCTS MARKET: EXPANSIONS, JANUARY 2022–MARCH 2025 263 TABLE 230 DRUG DEVICE COMBINATION PRODUCTS MARKET: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 265 TABLE 231 ABBOTT: COMPANY OVERVIEW 266 TABLE 232 ABBOTT: PRODUCTS OFFERED 267 TABLE 233 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 268 TABLE 234 ABBOTT: DEALS, JANUARY 2022–MARCH 2025 269 TABLE 235 ELI LILLY AND COMPANY: COMPANY OVERVIEW 270 TABLE 236 ELI LILLY AND COMPANY: PRODUCTS OFFERED 271 TABLE 237 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025 273 TABLE 238 ELI LILLY AND COMPANY: DEALS, JANUARY 2022–MARCH 2025 274 TABLE 239 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022–MARCH 2025 275 TABLE 240 ELI LILLY AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 276 TABLE 241 MEDTRONIC: COMPANY OVERVIEW 278 TABLE 242 MEDTRONIC: PRODUCTS OFFERED 279 TABLE 243 MEDTRONIC: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 281 TABLE 244 MEDTRONIC: DEALS, JANUARY 2022–MARCH 2025 282 TABLE 245 NOVO NORDISK A/S: COMPANY OVERVIEW 284 TABLE 246 NOVO NORDISK A/S: PRODUCTS OFFERED 285 TABLE 247 NOVO NORDISK A/S: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 286 TABLE 248 NOVO NORDISK A/S: DEALS, JANUARY 2022–MARCH 2025 287 TABLE 249 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022–MARCH 2025 288 TABLE 250 NOVARTIS AG: COMPANY OVERVIEW 291 TABLE 251 NOVARTIS AG: PRODUCTS OFFERED 292 TABLE 252 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025 294 TABLE 253 NOVARTIS AG: DEALS, JANUARY 2022–MARCH 2025 294 TABLE 254 NOVARTIS AG: EXPANSIONS, JANUARY 2022–MARCH 2025 295 TABLE 255 SANOFI: COMPANY OVERVIEW 297 TABLE 256 SANOFI: PRODUCTS OFFERED 298 TABLE 257 SANOFI: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025 299 TABLE 258 SANOFI: DEALS, JANUARY 2022–MARCH 2025 300 TABLE 259 SANOFI: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 301 TABLE 260 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW 302 TABLE 261 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED 303 TABLE 262 BOSTON SCIENTIFIC CORPORATION: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025 305 TABLE 263 BOSTON SCIENTIFIC CORPORATION: DEALS, JANUARY 2022–MARCH 2025 305 TABLE 264 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 306 TABLE 265 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 307 TABLE 266 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2022–MARCH 2025 308 TABLE 267 BECTON, DICKINSON AND COMPANY: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 308 TABLE 268 MERCK KGAA: COMPANY OVERVIEW 309 TABLE 269 MERCK KGAA: PRODUCTS OFFERED 310 TABLE 270 MERCK KGGA: DEALS, JANUARY 2022–MARCH 2025 311 TABLE 271 ABBVIE INC.: COMPANY OVERVIEW 312 TABLE 272 ABBVIE INC.: PRODUCTS OFFERED 313 TABLE 273 ABBVIE INC: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025 314 TABLE 274 ABBVIE INC.: DEALS, JANUARY 2022–MARCH 2025 315 TABLE 275 ABBVIE INC.: EXPANSIONS, JANUARY 2022–MARCH 2025 315 TABLE 276 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW 316 TABLE 277 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED 317 TABLE 278 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS, JANUARY 2022–MARCH 2025 318 TABLE 279 TEVA PHARMACEUTICAL INDUSTRIES LTD.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025 318 TABLE 280 STRYKER: COMPANY OVERVIEW 319 TABLE 281 STRYKER: PRODUCTS OFFERED 320 TABLE 282 B. BRAUN SE: COMPANY OVERVIEW 321 TABLE 283 B. BRAUN SE: PRODUCTS OFFERED 322 TABLE 284 TERUMO CORPORATION: COMPANY OVERVIEW 323 TABLE 285 TERUMO CORPORATION: PRODUCTS OFFERED 324 TABLE 286 TERUMO CORPORATION: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022–MARCH 2025 325 TABLE 287 TANDEM DIABETES CARE, INC.: COMPANY OVERVIEW 326 TABLE 288 CEQUR SIMPLICITY: COMPANY OVERVIEW 326 TABLE 289 INTARCIA THERAPEUTICS, INC.: COMPANY OVERVIEW 327 TABLE 290 HALOZYME, INC.: COMPANY OVERVIEW 327 TABLE 291 KALEO, INC.: COMPANY OVERVIEW 328 TABLE 292 LEAD CHEMICAL CO., LTD.: COMPANY OVERVIEW 329 TABLE 293 PURDUE PHARMA L.P.: COMPANY OVERVIEW 329 TABLE 294 ALVOGEN: COMPANY OVERVIEW 330 TABLE 295 EVOLUTIS: COMPANY OVERVIEW 330 TABLE 296 MUNDIPHARMA INTERNATIONAL LIMITED: COMPANY OVERVIEW 331 TABLE 297 SPARSHA PHARMA INTERNATIONAL PVT. LTD.: COMPANY OVERVIEW 332 TABLE 298 SUPERNUS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 333 TABLE 299 ALCON INC.: COMPANY OVERVIEW 334 FIGURE 1 DRUG DEVICE COMBINATION PRODUCTS MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE 30 FIGURE 2 DRUG DEVICE COMBINATION PRODUCTS MARKET: YEARS CONSIDERED 31 FIGURE 3 DRUG DEVICE COMBINATION PRODUCTS MARKET: RESEARCH DESIGN 33 FIGURE 4 DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY DATA FROM SECONDARY SOURCES 35 FIGURE 5 DRUG DEVICE COMBINATION PRODUCTS MARKET: KEY PRIMARY SOURCES 36 FIGURE 6 DRUG DEVICE COMBINATION PRODUCTS MARKET: INSIGHTS FROM PRIMARIES 37 FIGURE 7 DRUG DEVICE COMBINATION PRODUCTS MARKET: BREAKDOWN OF PRIMARIES (BY COMPANY TYPE, DESIGNATION, AND REGION) 37 FIGURE 8 DRUG DEVICE COMBINATION PRODUCTS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 38 FIGURE 9 DRUG DEVICE COMBINATION PRODUCTS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2024) 38 FIGURE 10 PEN INJECTORS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH) 39 FIGURE 11 AUTOINJECTORS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH) 40 FIGURE 12 DRUG DEVICE COMBINATION PRODUCTS MARKET: TOP-DOWN APPROACH 41 FIGURE 13 DRUG DEVICE COMBINATION PRODUCTS MARKET: CAGR PROJECTIONS (SUPPLY SIDE) 42 FIGURE 14 DRUG DEVICE COMBINATION PRODUCTS MARKET: DATA TRIANGULATION 43 FIGURE 15 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY PRODUCT TYPE, 2025 VS. 2030 (USD BILLION) 46 FIGURE 16 DRUG DEVICE COMBINATION PRODUCTS MARKET FOR INJECTABLE DRUG DELIVERY DEVICES, BY TYPE, 2025 VS. 2030 (USD BILLION) 47 FIGURE 17 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY APPLICATION, 2025 VS. 2030 (USD BILLION) 48 FIGURE 18 DRUG DEVICE COMBINATION PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD BILLION) 49 FIGURE 19 REGIONAL SNAPSHOT OF DRUG DEVICE COMBINATION PRODUCTS MARKET 50 FIGURE 20 INCREASING NUMBER OF REGULATORY APPROVALS AND RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET 51 FIGURE 21 CHINA AND DIABETES MANAGEMENT SEGMENT COMMANDED LARGEST MARKET SHARE IN 2024 52 FIGURE 22 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 53 FIGURE 23 DRUG DEVICE COMBINATION PRODUCTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54 FIGURE 24 DISABILITY-ADJUSTED LIFE YEARS FOR INDIVIDUALS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN AUSTRALIA, BY AGE (2023) 56 FIGURE 25 SHARE OF GLOBAL GERIATRIC POPULATION (ABOVE 60 YEARS), BY REGION, 2010 VS. 2015 VS. 2030 (PROJECTED) 57 FIGURE 26 DRUG DEVICE COMBINATION PRODUCTS MARKET: PORTER’S FIVE FORCES ANALYSIS 67   FIGURE 27 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF DRUG DEVICE COMBINATION PRODUCTS 69 FIGURE 28 KEY BUYING CRITERIA FOR DRUG DEVICE COMBINATION PRODUCTS 70 FIGURE 29 DRUG DEVICE COMBINATION PRODUCTS MARKET: PATENT PUBLICATION TRENDS AND TOP APPLICANT ANALYSIS (JANUARY 2014–APRIL 2025) 80 FIGURE 30 TOP PATENT APPLICANTS FOR DRUG DEVICE COMBINATION PRODUCTS, BY JURISDICTION (JANUARY 2014–APRIL 2025) 81 FIGURE 31 DRUG DEVICE COMBINATION PRODUCTS MARKET: VALUE CHAIN ANALYSIS 89 FIGURE 32 DRUG DEVICE COMBINATION PRODUCTS MARKET: ADJACENT MARKETS 92 FIGURE 33 DRUG DEVICE COMBINATION PRODUCTS MARKET: ECOSYSTEM ANALYSIS 93 FIGURE 34 DRUG DEVICE COMBINATION PRODUCTS MARKET: SUPPLY CHAIN ANALYSIS 97 FIGURE 35 DRUG DEVICE COMBINATION PRODUCTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 97 FIGURE 36 DRUG DEVICE COMBINATION PRODUCTS MARKET: FUNDING AND NUMBER OF DEALS, 2019–2023 98 FIGURE 37 DRUG DEVICE COMBINATION PRODUCTS MARKET: IMPACT OF AI/GEN AI 103 FIGURE 38 NORTH AMERICA: DRUG DEVICE COMBINATION PRODUCTS MARKET SNAPSHOT 166 FIGURE 39 ASIA PACIFIC: DRUG DEVICE COMBINATION PRODUCTS MARKET SNAPSHOT 196 FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET (2020–2024) 245 FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN AUTOINJECTORS MARKET (2024) 246 FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PEN INJECTORS MARKET (2024) 247 FIGURE 43 MARKET SHARE ANALYSIS OF KEY PLAYERS IN TRANSDERMAL PATCHES MARKET (2024) 248 FIGURE 44 RANKING OF KEY PLAYERS IN DRUG DEVICE COMBINATION PRODUCTS MARKET (2024) 250 FIGURE 45 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 252 FIGURE 46 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY FOOTPRINT 253 FIGURE 47 DRUG DEVICE COMBINATION PRODUCTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 258 FIGURE 48 EV/EBITDA OF KEY VENDORS 260 FIGURE 49 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 260 FIGURE 50 DRUG DEVICE COMBINATION PRODUCTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 261 FIGURE 51 ABBOTT: COMPANY SNAPSHOT 267 FIGURE 52 ELI LILLY AND COMPANY: COMPANY SNAPSHOT 271 FIGURE 53 MEDTRONIC: COMPANY SNAPSHOT 279 FIGURE 54 NOVO NORDISK A/S: COMPANY SNAPSHOT 285 FIGURE 55 NOVARTIS AG: COMPANY SNAPSHOT 292 FIGURE 56 SANOFI: COMPANY SNAPSHOT 298 FIGURE 57 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT 303 FIGURE 58 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT 307 FIGURE 59 MERCK KGAA: COMPANY SNAPSHOT 310   FIGURE 60 ABBVIE INC.: COMPANY SNAPSHOT 313 FIGURE 61 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT 316 FIGURE 62 STRYKER: COMPANY SNAPSHOT 320 FIGURE 63 B. BRAUN SE: COMPANY SNAPSHOT 322 FIGURE 64 TERUMO CORPORATION: COMPANY SNAPSHOT 324